Re-Evaluation of Toxicity and Long-Term Follow-Up of Isolated Lung Perfusion With Melphalan in Patients With Resectable Pulmonary Metastases: A Phase I and Extension Trial

Annals of Thoracic Surgery

Volumn 83, Issue 3, 2007, Pages 1235-1236

  Grootenboers, Marco J J H ^a   Schramel, Franz M N H ^a   van Boven, Wim J ^a   van Putte, Bart P ^a   Hendriks, Jeroen M H ^b   Van Schil, Paul E Y ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

CANCER SURGERY; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; EMPYEMA; FEASIBILITY STUDY; FOLLOW UP; HUMAN; HYPERTHERMIC THERAPY; ISOLATED LUNG; LETTER; LONG TERM CARE; LUNG LOBECTOMY; LUNG METASTASIS; LUNG PERFUSION; LUNG TOXICITY; MORBIDITY; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECURRENT DISEASE; RHABDOMYOLYSIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; HYPERTHERMIA, INDUCED; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MELPHALAN; PREOPERATIVE CARE;

EID: 33847335503     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2006.09.061     Document Type: Letter

References (1)

1. Hendriks J.M., Grootenboers M.J., Schramel F.M., et al. Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial. Ann Thorac Surg 78 (2004) 1919-1927